血清SMP30及抗SMP30抗体在肝细胞癌中的诊断价值
Diagnostic Value of Serum SMP30 and Anti-SMP30 Antibody in Hepatocellular Carcinoma.
作者信息
Zheng Shun-Xin, Xiang Bang-De, Long Jia-Min, Qu Cong, Mo Zhi-Jing, Li Kun, Zhuang Yuan, Lv Zhi-Lue, Zhou Su-Fang
机构信息
Department of Biochemistry and Molocular Biology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China.
出版信息
Lab Med. 2018 Jul 5;49(3):203-210. doi: 10.1093/labmed/lmy004.
OBJECTIVE
To evaluate the clinical value of senescence marker protein 30 (SMP30) and anti-SMP30 antibody in serum.
METHODS
We used enzyme-linked immunosorbent assay (ELISA) to analytically validate serum levels of SMP30 and anti-SMP30 antibody in 143 patients with hepatocellular carcinoma (HCC), compared with those levels in serum from 137 patients with chronic hepatitis (CH), 51 with liver cirrhosis (LC), and 165 healthy control individuals.
RESULTS
The positivity rate of SMP30 in the HCC group (8.39%) was significantly higher than that rate in the CH group (.73%) and in the healthy control group (1.21%). The positivity rate for anti-SMP30 antibody in patients with HCC was 25.87%, that in the CH group was 4.38%, and that in the LC group was 3.92%.
CONCLUSION
Anti-SMP30 antibody levels can be used as a biomarker for diagnosing HCC; marked results have been observed for patients with alpha-fetoprotein (AFP) negativity, in particular.
目的
评估血清中衰老标志物蛋白30（SMP30）及抗SMP30抗体的临床价值。
方法
我们采用酶联免疫吸附测定（ELISA）法对143例肝细胞癌（HCC）患者血清中SMP30及抗SMP30抗体水平进行分析验证，并与137例慢性肝炎（CH）患者、51例肝硬化（LC）患者及165例健康对照者血清中的相应水平作比较。
结果
HCC组中SMP30的阳性率（8.39%）显著高于CH组（0.73%）及健康对照组（1.21%）。HCC患者中抗SMP30抗体的阳性率为25.87%，CH组为4.38%，LC组为3.92%。
结论
抗SMP30抗体水平可作为诊断HCC的生物标志物；尤其在甲胎蛋白（AFP）阴性的患者中观察到显著结果。
Zotero 插件